Reviewing Liminatus Pharma (LIMN) & Its Rivals

Liminatus Pharma (NASDAQ:LIMN) is one of 861 public companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Liminatus Pharma to related businesses based on the strength of its risk, dividends, analyst recommendations, earnings, valuation, institutional ownership and profitability.

Risk and Volatility

Liminatus Pharma has a beta of 5.34, meaning that its stock price is 434% more volatile than the S&P 500. Comparatively, Liminatus Pharma’s peers have a beta of 1.23, meaning that their average stock price is 23% more volatile than the S&P 500.

Profitability

This table compares Liminatus Pharma and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Liminatus Pharma	N/A	N/A	-256.58%
Liminatus Pharma Competitors	-9,388.21%	-127.85%	-33.50%

Institutional and Insider Ownership

47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 19.4% of Liminatus Pharma shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Liminatus Pharma and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liminatus Pharma	1	0	0	0	1.00
Liminatus Pharma Competitors	9352	14861	44452	1502	2.54

As a group, “Biotechnology” companies have a potential upside of 59.37%. Given Liminatus Pharma’s peers stronger consensus rating and higher probable upside, analysts plainly believe Liminatus Pharma has less favorable growth aspects than its peers.

Valuation & Earnings

This table compares Liminatus Pharma and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Liminatus Pharma	N/A	-$10.21 million	-0.18
Liminatus Pharma Competitors	$697.66 million	$10.34 million	-11.85

Liminatus Pharma’s peers have higher revenue and earnings than Liminatus Pharma. Liminatus Pharma is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

Liminatus Pharma peers beat Liminatus Pharma on 8 of the 13 factors compared.

About Liminatus Pharma

Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.